An IPF-like disease course in disorders other than IPF: how can this be anticipated, recognized, and managed?

References

• Lederer DJ, Martinez FJ, Longo DL. Idiopathic pulmonary fibrosis. N Engl J Med. 2018;378(19):1811–1823.
   PubMed Web of Science ®Google Scholar
• Duchemann B, Annesi-Maesano I, Jacobe de Naurois C, et al. Prevalence and incidence of interstitial lung diseases in a multi-ethnic county of greater Paris. Eur Respir J. 2017;50(2):1602419.
   PubMed Web of Science ®Google Scholar
• De Sadeleer LJ, Meert C, Yserbyt J, et al. Diagnostic ability of a dynamic multidisciplinary discussion in interstitial lung diseases: a retrospective observational study of 938 cases. Chest. 2018;153(6):1416–1423.
   PubMed Web of Science ®Google Scholar
• Skeoch S, Weatherley N, Swift AJ, et al. Drug-Induced Interstitial Lung Disease: a Systematic Review. J Clin Med. 2018 Oct 15;7(10):356.
   PubMed Web of Science ®Google Scholar
• Spagnolo P, Rossi G, Trisolini R, et al. Pulmonary sarcoidosis. Lancet Respir Med. 2018;6(5):389–402.
   PubMed Web of Science ®Google Scholar
• Belloli EA, Beckford R, Hadley R, et al. Idiopathic non-specific interstitial pneumonia. Respirology. 2016;21(2):259–268.
   PubMed Web of Science ®Google Scholar
• Cottin V, Wells A. Unclassified or unclassifiable interstitial lung disease: confusing or helpful disease category? Eur. Respir J. 2013;42(3):576–579.
   PubMed Web of Science ®Google Scholar
• Hyldgaard C, Bendstrup E, Wells AU, et al. Unclassifiable interstitial lung diseases: clinical characteristics and survival. Respirology. 2017;22(3):494–500.
   PubMed Web of Science ®Google Scholar
• Ryerson CJ, Corte TJ, Lee JS, et al. A standardized diagnostic ontology for fibrotic interstitial lung disease. an international working group perspective. Am J Respir Crit Care Med. 2017;196(10):1249–1254.
   PubMed Web of Science ®Google Scholar
• Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788–824.
   PubMed Web of Science ®Google Scholar
• Lynch DA, Sverzellati N, Travis WD, et al. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner society white paper. Lancet Respir Med. 2018 Feb;6(2):138–153.
   PubMed Web of Science ®Google Scholar
• Wells AU, Approach to diagnosis of diffuse lung disease. Clinical respiratory medicine, 2nd. Albert RK, Spiro SG, Jett JR. editors, Philadelphia: Mosby/Elsevier. 2004, p. 647-656.
   Google Scholar
• Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European respiratory society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188(6):733–748.
   PubMed Web of Science ®Google Scholar
• Wells AU, Brown KK, Flaherty KR, et al. What’s in a name? That which we call IPF, by any other name would act the same. Eur Respir J. 2018 May 17;51(5):1800692.
   PubMed Web of Science ®Google Scholar
• Brown KK, Martinez FJ, Walsh SLF, et al., The natural history of progressive fibrosing interstitial lung diseases. Eur Respir J. 55(6): 2000085. 2020.
   PubMed Web of Science ®Google Scholar
• Gimenez A, Storrer K, Kuranishi L, et al. Change in FVC and survival in chronic fibrotic hypersensitivity pneumonitis. Thorax. 2018 Apr;73(4):391–392.
   PubMed Web of Science ®Google Scholar
• Wang P, Jones KD, Urisman A, et al. Pathologic findings and prognosis in a large prospective cohort of chronic hypersensitivity pneumonitis. Chest. 2017 Sep;152(3):502–509.
   PubMed Web of Science ®Google Scholar
• Salisbury ML, Gu T, Murray S, et al. Hypersensitivity pneumonitis: radiologic phenotypes are associated with distinct survival time and pulmonary function trajectory. Chest. 2018 Sep 19;pii:S0012-3692(18)32438–3.
   Google Scholar
• Walsh SL, Wells AU, Sverzellati N, et al. Relationship between fibroblastic foci profusion and high resolution CT morphology in fibrotic lung disease. BMC Med. 2015 Sep;13(1):241.
   PubMedGoogle Scholar
• Chiba S, Tsuchiya K, Akashi T, et al. Chronic hypersensitivity pneumonitis with a usual interstitial pneumonia-like pattern: correlation between histopathologic and clinical findings. Chest. 2016 Jun;149(6):1473–1481.
   PubMed Web of Science ®Google Scholar
• Walsh SLF, Wells AU, Desai SR, et al. Multicentre evaluation of multidisciplinary team meeting agreement on diagnosis in diffuse parenchymal lung disease: a case-cohort study. Lancet Respir Med. 2016;4(7):557–565.
   PubMed Web of Science ®Google Scholar
• Ravaglia C, Wells AU, Tomassetti S, et al. Diagnostic yield and risk/benefit analysis of trans-bronchial lung cryobiopsy in diffuse parenchymal lung diseases: a large cohort of 699 patients. BMC Pulm Med. 2019 Jan 16;19(1):16.
   PubMedGoogle Scholar
• Troy LK, Grainge C, Corte TJ, et al. Diagnostic accuracy of transbronchial lung Cryobiopsy for Interstitial Lung Disease Diagnosis (COLDICE): a prospective, comparative study. 2019 Sep 27[ Online ahead of print]
   Google Scholar
• Walsh SL, Sverzellati N, Devaraj A, et al. Chronic hypersensitivity pneumonitis: high resolution computed tomography patterns and pulmonary function indices as prognostic determinants. Eur Radiol. 2012 Aug;22(8):1672–1679.
   PubMed Web of Science ®Google Scholar
• Bouros D, Wells AU, Nicholson AG, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med. 2002 Jun 15;165(12):1581–1586.
   PubMed Web of Science ®Google Scholar
• Ryerson CJ, Vittinghoff E, Ley B, et al. Predicting survival across chronic interstitial lung disease: the ILD-GAP model. Chest. 2014;145(4):723–728.
   PubMed Web of Science ®Google Scholar
• Goh NS, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med. 2008 Jun 1;177(11):1248–1254.
   PubMed Web of Science ®Google Scholar
• Jacob J, Hirani N, van Moorsel CHM, et al. Predicting outcomes in rheumatoid arthritis related interstitial lung disease. Eur Respir J. 2019 Jan 3;53(1):1800869. pii
   PubMed Web of Science ®Google Scholar
• Zamora-Legoff JA, Krause ML, Crowson CS, et al. Patterns of interstitial lung disease and mortality in rheumatoid arthritis. Rheumatology (Oxford). 2017 Mar 1;56(3):344–350.
   PubMed Web of Science ®Google Scholar
• Kelly CA, Saravanan V, Nisar M, et al. Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics--a large multicentre UK study. Rheumatology (Oxford). 2014 Sep;53(9):1676–1682.
   PubMed Web of Science ®Google Scholar
• Kim EJ, Collard HR, King TE Jr. Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern. Chest. 2009 Nov;136(5):1397–1405.
   PubMed Web of Science ®Google Scholar
• Kim EJ, Elicker BM, Maldonado F, et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J. 2010 Jun;35(6):1322–1328.
   PubMed Web of Science ®Google Scholar
• Nurmi HM, Kettunen HP, Suoranta SK, et al. Several high-resolution computed tomography findings associate with survival and clinical features in rheumatoid arthritis-associated interstitial lung disease. Respir Med. 2018Jan;134:24–30.
   PubMed Web of Science ®Google Scholar
• Walsh SL, Sverzellati N, Devaraj A, et al., Connective tissue disease related fibrotic lung disease: high resolution computed tomographic and pulmonary function indices as prognostic determinants. Thorax. 69(3): 216–222. 2014.
   PubMed Web of Science ®Google Scholar
• Fischer A, Antoniou KM, Brown KK, et al. An official European respiratory society/American thoracic society research statement: interstitial pneumonia with autoimmune features. Eur Respir J. 2015 Oct;46(4):976–987.
   PubMed Web of Science ®Google Scholar
• Latsi PI, du Bois RM, Nicholson AG, et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med. 2003 Sep 1;168(5):531–537.
   PubMed Web of Science ®Google Scholar
• Kambouchner M, Levy P, Nicholson AG, et al. Prognostic relevance of histological variants in nonspecific interstitial pneumonia. Histopathology. 2014;65(4):549–560.
   PubMed Web of Science ®Google Scholar
• Ebner L, Christodoulidis S, Stathopoulou T, et al. Meta-analysis of the radiological and clinical features of Usual Interstitial Pneumonia (UIP) and Nonspecific Interstitial Pneumonia (NSIP). PLoS One. 2020 Jan 13;15(1):e0226084.
   PubMed Web of Science ®Google Scholar
• Ryerson CJ, Urbania TH, Richeldi L, et al. Prevalence and prognosis of unclassifiable interstitial lung disease. Eur Respir J. 2013 Sep;42(3):750–757.
   PubMed Web of Science ®Google Scholar
• Jacob J, Bartholmai BJ, Rajagopalan S, et al. Unclassifiable-interstitial lung disease: outcome prediction using CT and functional indices. Respir Med. 2017 Sep;130:43–51.
   PubMed Web of Science ®Google Scholar
• Kenmotsu H, Naito T, Kimura M, et al. The risk of cytotoxic chemotherapy-related exacerbation of interstitial lung disease with lung cancer. J Thorac Oncol. 2011 Jul;6(7):1242–1246.
   PubMed Web of Science ®Google Scholar
• Walsh SL, Wells AU, Sverzellati N, et al. An integrated clinicoradiological staging system for pulmonary sarcoidosis: a case-cohort study. Lancet Respir Med. 2014 2; 2(2): 123–130.
   PubMed Web of Science ®Google Scholar
• Nunes H, Schubel K, Piver D, et al. Nonspecific interstitial pneumonia: survival is influenced by the underlying cause. Eur Respir J. 2015;45(3):746–755.
   PubMed Web of Science ®Google Scholar
• Zamora-Legoff JA, Krause ML, Crowson CS, et al. Progressive decline of lung function in rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheumatol. 2017 Mar;69(3):542–549.
   PubMed Web of Science ®Google Scholar
• Solomon JJ, Chung JH, Cosgrove GP, et al. Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J. 2016 Feb;47(2):588–596.
   PubMed Web of Science ®Google Scholar
• Goh NS, Hoyles RK, Denton CP, et al. Short-term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis. Arthritis Rheumatol. 2017 Aug;69(8):1670–1678.
   PubMed Web of Science ®Google Scholar
• Volkmann ER, Tashkin DP, Sim M, et al. Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts. Ann Rheum Dis. 2019 Jan;78(1):122–130.
   PubMed Web of Science ®Google Scholar
• Moore OA, Proudman SM, Goh N, et al. Quantifying change in pulmonary function as a prognostic marker in systemic sclerosis-related interstitial lung disease. Clin Exp Rheumatol. 2015;33(4 Suppl 91):S111–6.
   PubMed Web of Science ®Google Scholar
• Zappala CJ, Latsi PI, Nicholson AG, et al. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J. 2010 Apr;35(4):830–836.
   PubMed Web of Science ®Google Scholar
• du Bois RM, Weycker D, Albera C, et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med. 2011 Dec 15;184(12):1382–1389.
   PubMed Web of Science ®Google Scholar
• Schmidt SL, Tayob N, Han MK, et al. Predicting pulmonary fibrosis disease course from past trends in pulmonary function. Chest. 2014 Mar 1;145(3):579–585.
   PubMed Web of Science ®Google Scholar
• Ley B, Bradford WZ, Vittinghoff E, et al. Predictors of mortality poorly predict common measures of disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2016 Sep 15;194(6):711–718.
   PubMed Web of Science ®Google Scholar
• Reichmann WM, Yu YF, Macaulay D, et al. Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis. BMC Pulm Med. 2015 Dec;15(1):167.
   PubMed Web of Science ®Google Scholar
• King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014 May 29;370(22):2083–2092.
   PubMed Web of Science ®Google Scholar
• Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014 May 29;370(22):2071–2082.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354(25):2655–2666.
   PubMed Web of Science ®Google Scholar
• Hoyles RK, Ellis RW, Wellsbury J, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 2006;54(12):3962–3970.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016 Sep;4(9):708–719.
   PubMed Web of Science ®Google Scholar
• Herzog EL, Mathur A, Tager AM, et al. Review: interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct? Arthritis Rheumatol. 2014;66(8):1967–1978.
   PubMed Web of Science ®Google Scholar
• Kevin R, Flaherty KR, Wells AU, et al., Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 381(18): 1718–1727. 2019.
   PubMed Web of Science ®Google Scholar
• Behr J, Neuser P, Prasse A, et al. Exploring efficacy and safety of oral Pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) - a randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial. BMC Pulm Med. 2017 Sep 6;17(1):122.
   PubMedGoogle Scholar
• Maher TM, Corte TJ, Fischer A, et al. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 Trial. Lancet Respir Med. 2020;8:147-157.
   Web of Science ®Google Scholar
• Distler O, Highland KB, Gahlemann M, et al., Nintedanib for systemic sclerosis–associated interstitial lung disease. N Engl J Med. 380(26): 2518–2528. 2019.
   PubMed Web of Science ®Google Scholar
• Raghu G, KJ A, Jr KTE, et al. Idiopathic Pulmonary Fibrosis Clinical Research Network. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012 May 24;366(21):1968–1977.
   PubMed Web of Science ®Google Scholar
• Sharp C, McCabe M, Dodds N, et al. Rituximab in autoimmune connective tissue disease–associated interstitial lung disease. Rheumatology (Oxford). 2016 Jul;55(7):1318–1324.
   PubMed Web of Science ®Google Scholar
• Keir GJ, Maher TM, Hansell DM, et al. Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy. Eur Respir J. 2012 Sep;40(3):641–648.
   PubMed Web of Science ®Google Scholar
• Barba T, Fort R, Cottin V, et al. Treatment of idiopathic inflammatory myositis associated interstitial lung disease: a systematic review and meta-analysis. Autoimmun Rev. 2019 Feb;18(2):113–122.
   PubMed Web of Science ®Google Scholar
• Allenbach Y, Guiguet M, Rigolet A, et al. Efficacy of Rituximab in refractory inflammatory myopathies associated with anti- synthetase auto-antibodies: an open-label, phase II Trial. PLoS One. 2015 Nov 5;10(11):e0133702.
   PubMed Web of Science ®Google Scholar
• Andersson H, Sem M, Lund MB, et al. Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease. Rheumatology (Oxford). 2015;54(8):1420–1428.
   PubMed Web of Science ®Google Scholar
• DA Z, Schwarz M, KJ A, et al.; Idiopathic Pulmonary Fibrosis Clinical Research Network. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med. 2010;363:620–628.
   PubMed Web of Science ®Google Scholar
• Kolb M, Raghu G, Wells AU, et al. Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis. N Engl J Med. 2018 Nov 1;379(18):1722–1731.
   PubMed Web of Science ®Google Scholar